Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $7.00

Sana Biotechnology (NASDAQ:SANA) had its price target hoisted by Bank of America from $6.00 to $7.00 in a research report released on Tuesday,Benzinga reports. Bank of America currently has a buy rating on the stock.

SANA has been the subject of several other reports. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. JMP Securities set a $8.00 price target on shares of Sana Biotechnology in a research note on Thursday, October 30th. Citizens Jmp increased their target price on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a report on Monday, December 29th. Finally, Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

Sana Biotechnology Stock Down 4.4%

NASDAQ SANA opened at $4.52 on Tuesday. The stock’s 50-day moving average price is $4.28 and its 200-day moving average price is $4.00. The company has a market capitalization of $1.20 billion, a P/E ratio of -4.66 and a beta of 1.96. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Research analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of large investors have recently modified their holdings of the business. Marex Group plc purchased a new stake in shares of Sana Biotechnology in the second quarter valued at approximately $10,423,000. Vanguard Group Inc. lifted its stake in Sana Biotechnology by 19.9% during the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after purchasing an additional 1,517,474 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the period. Baillie Gifford & Co. lifted its holdings in Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after buying an additional 1,371,775 shares in the last quarter. Finally, Corient Private Wealth LLC raised its stake in shares of Sana Biotechnology by 264.7% in the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after acquiring an additional 824,505 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.